Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Description of Clinicians' Predictive Abilities Before and After a Diffusion Tensor Imaging (DTI)

NCT07863414 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-11
Last updated
2026-10-07

Condition(s) studied

Diffusion Tensor Imaging Prognosis

Investigational drug(s) / intervention(s)

Questionnaire

Questionnaire: Two clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis. A phone call will be made, blinded to the prognosis made before the MRI and without knowledge of the prognosis established by diffusion tensor MRI, 12 months after the brain injury. This call will be made by a person qualified to administer the questionnaires, in order to obtain a GOSE score.

Study summary

With a mortality rate of over 13% in the neuro-intensive care unit, 86% of which are related to the withdrawal of active treatment, predicting a reliable neurological prognosis is of paramount importance in neuro-intensive care to help clinicians inform family members appropriately and tailor care to the patient's presumed wishes. This also helps justify aggressive resuscitation in patients with a presumed good prognosis and, conversely, avoid keeping patients with a poor neurological prognosis alive against their presumed wishes.

Current guidelines recommend multimodal neuro-prognostication, in which the clinician synthesizes prognostic data from the clinical examination, EEG, plasma or CSF biomarkers, and imaging to collaboratively develop an individualized prognosis, even though no study has evaluated the quality of this multimodal prognosis. Furthermore, existing variations depending on the nosological context make this approach complex and likely difficult to replicate.

Brain MRI is an important tool for neuroprognostics in patients with neurological injuries, and for this reason it is commonly used in clinical practice as part of this multimodal approach.

More specifically, brain MRI with diffusion tensor sequences is a validated prognostic tool in post-anoxic coma and traumatic brain injury, as well as, more recently, in subarachnoid hemorrhage, strokes, and hypoglycemia. However, it has not yet been compared to multimodal neuroprognostics performed by the clinician.

The primary objective is to compare the prognostic performance of two prescribing clinicians with diffusion tensor MRI before and after the MRI scan is performed.

Primary outcome measure: to compare the prognostic performance regarding unfavorable outcomes (Glasgow Outcome Scale Extended \< 5) at 12 months between the two prescribing clinicians and diffusion tensor MRI before and after the MRI scan is performed.

A secondary objective will be, among other things, to study the informational gain provided by MRI in improving clinicians' predictions after receiving the MRI results.

Intensive care clinicians constitute the target population. These are clinicians caring for an intensive care patient with a brain injury who order a brain MRI for prognostic purposes as part of patient care and multimodal neuroprognostics.

On the day of the MRI, two clinicians will complete the research questionnaire assessing the patient's prognosis the day before or a few hours before the MRI (on the same day). Then, as soon as the MRI results are available, the same two clinicians will complete the same questionnaire assessing the patient's prognosis after reviewing the MRI results. Patient data regarding the pathology and prognostic factors will be collected at this time.

Finally, surviving patients will be interviewed at 1 year regarding their independence using the Glasgow Outcome Scale Extended (GOSE) and their quality of life using the Medical Outcomes Study Short Form General Health Survey (SF-12) via a telephone call.

We plan to include 220 patients and approximately 70 clinicians across 8 recruiting centers over a 2-year enrollment period. With a 12-month follow-up period, the total duration of the study will be 3 years.

The statistical analysis will include a description of clinicians' ability to distinguish patient prognosis by measuring the area under the Receiver Operating Characteristic (ROC) curve, or AUC. The prediction concerns an unfavorable outcome, defined as a GOSE score of 1 to 4. Since we had no pre-study data on clinicians' performance in predicting an unfavorable outcome at the time of a prognostic MRI, the inclusion target was set based on data from a previous study at 220 patients, which corresponds to the number of patients we planned to enroll over a 2-year period.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * For clinicians: * Clinicians with a medical degree * Prescribers of DTI for the following patients For patients : * Patients aged 18 years or older * Patients for whom a brain MRI with a DTI sequences is prescribed, during or following resuscitation as part of their care. * A close relative or trusted person informed of the research and who has not objected to the patient's participation in the study. Given the altered state of consciousness of these patients, the patient is unable to express their objection. Exclusion Criteria: For clinicians - Clinician's refusal to complete the study questionnaires For patients: \- DTI measurements (anisotropy fraction and mean diffusivity) not feasible before or after treatment

Primary outcome measure(s)

  • Clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE <5) — 1 day before or the day of the MRI and 12 months after the brain injury
    The primary outcome measure is the clinicians' ROC curve for predicting unfavorable patient outcomes at 12 months before MRI (Glasgow Outcome Scale Extended (GOSE \<5). Two clinicians will be interviewed the day before or the day of the brain MRI using a questionnaire. This questionnaire will also assess the physician's knowledge and the prognostic factors used to formulate their prognosis. The clinician prognosis will be a number between 0 and 100, given by the clinician after this short explanation. "Now that you have all prognostic factors in mind, we would like your estimate of the patient's risk of an unfavorable outcome, on a scale of 0 to 100. This refers to a person who is unable to go shopping or travel independently, and who is unable to live independently, corresponding to a GOSE less than 5, one year after their brain injury." We will use the average of the two prognoses to construct the ROC curve.

Trial sites (8)

FacilityCityRegionStatus
Réanimation Polyvalente, AP-HM La Timone Marseille France
Institut de cardiologie, réanimation médicale, hôpital Pitié-Salpêtrière Paris France
Réanimation Institut de Cardiologie, chirurgie cardiaque, hôpital Pitié Salpêtrière Paris France
Service de réanimation Babinski, Hôpital Pitié Salpêtrière Paris France
Service de Réanimation Eole, Hôpital Pitié Salpêtrière Paris France
Service de Réanimation Gaston Cordier, Hôpital Pitié Salpêtrière Paris France
Service de réanimation Husson Mourrier, hôpital Pitié-Salpêtrière Paris France
Service de Réanimation neurologie médicale, hôpital Pitié-Salpêtrière Paris France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07863414 on ClinicalTrials.gov ↗ ← All trials in France